SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a pacesetter in AI options for medical trials, in the present day introduced outcomes from a collaboration with remynd, a Belgium-based biotech firm growing therapies for neurodegenerative illnesses. The outcomes had been shared on the 2025 Alzheimer’s & Parkinson’s Drug Growth Summit in Boston.
The collaboration targeted on remynd’s Section 2a medical trial of REM127, an investigational, first-generation small molecule remedy focusing on septins in sufferers with mild-to-moderate Alzheimer’s Illness (AD). The examine enrolled a restricted variety of contributors and measured modifications in AD biomarkers over a brief therapy window.
Unlearn supported the examine by making use of its Alzheimer’s Illness-specific Digital Twin Generator (AD DTG)—a proprietary machine studying mannequin educated on knowledge from greater than 26,000 contributors throughout landmark AD datasets resembling ADNI, CPAD, NACC, and EPAD. The AD DTG makes use of every participant’s baseline knowledge to forecast their medical and biomarker trajectories underneath normal care, producing a “digital twin” for each particular person within the trial.
These digital twins served as individualized comparators, offering a further layer of proof to assist interpret modifications noticed within the handled inhabitants. This method is especially beneficial in early-phase research the place small pattern sizes restrict the flexibility to attract conclusions utilizing conventional statistical strategies alone.
“This can be a highly effective instance of how digital twins might help unlock insights from small research,” stated Steve Herne, CEO of Unlearn. “Our collaboration with remynd helped strengthen the proof behind REM127 and demonstrated the worth of utilizing AI to help smarter, quicker medical analysis.”
“The collaboration with Unlearn and the ensuing knowledge additional will increase our confidence in our pioneering method in direction of reaching symptomatic aid and illness modification in Alzheimer’s. It will help our efforts to advance an optimized second-generation remedy,” stated Gerard Griffioen, Ph.D., CSO of remynd. “Digital twins provide a brand new lens for deciphering biomarker tendencies over time—particularly in early-stage trials the place each knowledge level issues.”
For extra data, go to www.unlearn.ai or comply with us on LinkedIn and X/Twitter.
